ICLR vs LH vs NTRB Stock Comparison

Icon, Labcorp Holdings and NutriBand Prices as of Nov 2, 2026 Peers: Industry group
1 more company in this comparison (LDOS) Create a free account to keep reading and compare up to 10 companies.
ICLR Icon Plc
$205.14 +26.6% 1M +19.4% 1Y
Market cap
$15.71B
P/E
35.9x
Revenue (TTM)
$8.23B
Div. yield
–
Contract Research Healthcare
1 win
LH Labcorp Holdings Inc.
$355.65 +15.3% 1M +40.0% 1Y
Market cap
$28.77B
P/E
28.9x
Revenue (TTM)
$14.59B
Div. yield
0.81%
Diagnostic Labs Healthcare
8 wins
NTRB NutriBand Inc.
$6.41 -12.0% 1M -4.8% 1Y
Market cap
$77.92M
P/E
–
Revenue (TTM)
$1.62M
Div. yield
–
Generic Drugs Healthcare
2 wins

Head to Head

11 decided of 12

Labcorp Holdings leads on 8 of the 12 questions below (Labcorp Holdings 8, NutriBand 2, Icon 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionICLRLHNTRBLeader
Larger companyMarket capitalisation $15.71B $28.77B $77.92M LH
Cheaper on earningsLower P/E, profitable companies only 35.9x 28.9x -11.2x LH
Cheaper on forward earningsLower price / next fiscal year consensus EPS 20.0x 20.8x 3.9x NTRB
Faster revenue growthRevenue growth, trailing twelve months +1.8% +6.0% -37.3% LH
More profitableNet margin, trailing twelve months 5.4% 6.9% -430.4% LH
Better return on capitalReturn on invested capital 4.7% 8.5% — LH
Less leveragedLower net debt / EBITDA 2.3x 2.5x 0.5x NTRB
Higher dividend yieldTrailing dividend yield — 0.81% — –
Better 1-year returnPrice return, last 12 months +19.4% +40.0% -4.8% LH
Better 5-year returnAnnualised price return, 5 years -5.7%/yr +7.6%/yr +6.3%/yr LH
Less volatileAnnualised volatility, 1 year 75.1% 24.4% 79.0% LH
Higher overall scoreMean of the five percentile scores vs peers 79/100 57/100 50/100 ICLR

Percentile Scorecard

ICLRLHNTRB

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisICLRLHNTRB
Valuation 90 #2 of 11 61 #37 of 94 54 #290 of 623
Growth 70 #4 of 11 35 #57 of 87 43 #346 of 601
Profitability 80 #3 of 11 71 #26 of 86 35 #359 of 553
Financial Health 75 #4 of 13 45 #55 of 99 68 #211 of 654
Shareholder Returns – 71 #17 of 56 –
Overall 79 57 50
  • ICLR ranked among 13 companies in Pharma Services
  • LH ranked among 102 companies in Healthcare Providers
  • NTRB ranked among 671 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodICLRLHNTRBSPY
1 month +26.6%+15.3%-12.0% -2.3%
3 months +29.5%+15.6%+128.1% -0.7%
6 months +83.2%+40.6%+73.2% +4.8%
Year to date +12.6%+41.8%+41.2% +10.3%
1 year +19.4%+40.0%-4.8% +10.3%
3 years -20.5%+69.2%+199.5% +73.0%
3 years, per year -7.4%+19.2%+44.2% +20.1%
5 years -25.6%+44.0%+35.5% +61.9%
5 years, per year -5.7%+7.6%+6.3% +10.1%
10 years +167.1%+233.8%— +258.6%
10 years, per year +10.3%+12.8%— +13.6%

Risk

MeasureICLRLHNTRBSPY
Volatility, 1Y 75.1%24.4%79.0% 12.8%
Downside volatility, 1Y 87.8%21.8%73.9% 12.8%
Beta vs S&P 500, 1Y 1.480.391.08 1.00
Return / volatility, 1Y 0.261.64-0.06 0.80
Max drawdown, 5Y -76.9%-35.0%-77.7% -25.4%
From 52-week high -4.8%-3.4%-28.7% -3.5%
52-week high $215.48$368.15$8.99 $779.14
52-week low $80.08$246.64$2.81 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleICLRLHNTRB
P/E now vs peer median 35.9xmedian 35.0x 28.9xmedian 25.3x -11.2xmedian 17.4x
P/S now vs peer median 1.9xmedian 2.5x 2.0xmedian 1.5x 48.2xmedian 8.9x
EV/EBITDA now vs peer median 16.7xmedian 28.8x 15.5xmedian 14.6x -10.8xmedian 17.0x
P/FCF now vs peer median 18.3xmedian 20.5x 22.4xmedian 21.6x -21.5xmedian 21.4x
P/B now vs peer median 1.7xmedian 2.7x 3.3xmedian 3.1x 14.6xmedian 2.1x
PEG now vs peer median -11.96median 1.94 1.68median 0.83 -13.63median 0.35

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsICLRLHNTRB
Revenue $8.23B $14.59B $1.62M
Gross profit $1.93B $4.23B $536.12K
Operating income $718.25M $1.50B -$7.05M
Net income $448.66M $1.00B -$6.96M
Free cash flow $857.06M $1.29B -$3.63M
R&D – – $1.21M
EPS (diluted) $5.68 $12.24 $-0.57
Cash & equivalents $808.98M $261.80M $3.42M
Total debt $3.38B $5.85B $153.54K
Shares (diluted) 78.97M 82.00M 12.16M
Enterprise value $12.48B $26.87B $60.60M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricICLRLHNTRB
P/E 35.9x 28.9x -11.2x
P/FCF 18.3x 22.4x -21.5x
P/Operating cash flow 15.3x 15.9x -21.5x
P/S 1.9x 2.0x 48.2x
P/B 1.7x 3.3x 14.6x
P/Tangible book 2.6x 5.6x 15.1x
EV/EBITDA 16.7x 15.5x -10.8x
EV/EBIT 25.4x 22.9x -10.6x
EV/Revenue 2.2x 2.4x 46.1x
EV/FCF 21.3x 26.7x -20.6x
EV/Operating cash flow 17.8x 18.9x -20.6x
PEG (3Y EPS CAGR) -11.96 1.68 -13.63

Growth

14 metrics
MetricICLRLHNTRB
Revenue growth (1Y) 1.8% 6.0% -37.3%
Revenue CAGR (3Y) 0.9% 6.6% -10.8%
Gross profit growth (1Y) -13.4% 8.0% -39.5%
Gross profit CAGR (3Y) -6.5% 8.2% -16.5%
Operating income growth (1Y) 53.9% 12.6% 32.3%
Operating income CAGR (3Y) -7.0% 19.7% -15.3%
Net income growth (1Y) 55.9% 17.4% 32.2%
Net income CAGR (3Y) -4.4% 14.9% -14.8%
EPS growth (1Y) 30.1% 19.8% 80.0%
EPS CAGR (3Y) -3.0% 17.2% 0.8%
Operating cash flow growth (1Y) -9.9% 0.6% 25.9%
Operating cash flow CAGR (3Y) 15.8% 9.0% -5.7%
Free cash flow growth (1Y) -11.1% -6.8% 26.6%
Free cash flow CAGR (3Y) 18.4% 8.2% -5.5%

Profitability

14 metrics
MetricICLRLHNTRB
Gross margin 23.4% 29.0% 33.1%
EBITDA margin 13.3% 15.1% -426.5%
Operating margin 8.7% 10.3% -435.6%
Pretax margin 6.3% 8.4% -430.4%
Net margin 5.4% 6.9% -430.4%
FCF margin 10.4% 8.8% -224.5%
Operating cash flow margin 12.5% 12.4% -224.5%
Return on equity 7.6% 11.5% -123.0%
Return on assets 4.3% 5.4% -105.6%
Return on invested capital 4.7% 8.5% –
Return on capital employed 5.3% 9.4% -123.9%
Asset turnover 0.5x 0.8x 0.2x
Cash conversion (OCF / net income) 2.3x 1.8x 0.5x
Stock comp / revenue 1.1% 0.9% 204.1%

Financial Health

11 metrics
MetricICLRLHNTRB
Debt / assets 20.8% 30.9% 2.4%
Debt / equity 0.4x 0.7x 0.0x
Net debt / EBITDA 2.3x 2.5x 0.5x
Debt / FCF 3.9x 4.5x 0.0x
Liabilities / assets 43.8% 53.2% 15.3%
Equity / assets 56.2% 46.8% 84.7%
Interest coverage 3.4x 6.5x -339.3x
Current ratio 1.3x 1.4x 4.2x
Quick ratio 0.9x 1.0x 3.8x
Cash ratio 0.3x 0.1x 3.8x
Altman Z-score 2.22 3.48 34.74

Shareholder Returns

7 metrics
MetricICLRLHNTRB
Dividend yield – 0.8% –
Net buyback yield 2.4% 2.1% –
Shareholder yield 2.4% 2.9% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusICLRLHNTRB
Forward P/E 20.0xFY2026 20.8xFY2026 3.9xFY2026
EPS, next fiscal year $10.25FY2026 $17.07FY2026 $1.65FY2026
EPS growth, next FY -18.2%FY2026 +3.8%FY2026 –
EPS growth, the year after +22.2% +9.3% +112.1%
Revenue, next fiscal year $8.52BFY2026 $14.31BFY2026 $90.32MFY2026
Revenue growth, next FY +3.2%FY2026 +2.6%FY2026 +4,334.5%FY2026
Revenue growth, the year after -3.2% +11.9% +109.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersICLRLHNTRB
Held by institutions 100.0% 97.0% –
Institutions holding 424 1,053 –
Change in shares held, QoQ +5.5% +1.6% –
Institutions buying 234 466 –
Institutions selling 139 393 –
Buyers to sellers 1.68 1.19 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ICLRLHNTRB
ICLR 1.00 0.36 0.17
LH 0.36 1.00 0.18
NTRB 0.17 0.18 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ICLR, LH and NTRB?

Labcorp Holdings (LH) is the largest by market capitalisation: Icon (ICLR) $15.71B, Labcorp Holdings (LH) $28.77B, NutriBand (NTRB) $77.92M.

Which stock is cheaper, ICLR, LH and NTRB?

Labcorp Holdings (LH) trades on the lowest price-to-earnings ratio (Icon (ICLR) 35.9x, Labcorp Holdings (LH) 28.9x, NutriBand (NTRB) -11.2x). On next year's consensus earnings, NutriBand (NTRB) is cheapest (Icon (ICLR) 20.0x, Labcorp Holdings (LH) 20.8x, NutriBand (NTRB) 3.9x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Labcorp Holdings (LH) grew revenue fastest over the trailing twelve months: Icon (ICLR) +1.8%, Labcorp Holdings (LH) +6.0%, NutriBand (NTRB) -37.3%.

Which company is more profitable?

Labcorp Holdings (LH) has the highest net margin (Icon (ICLR) 5.4%, Labcorp Holdings (LH) 6.9%, NutriBand (NTRB) -430.4%). On return on invested capital, Labcorp Holdings (LH) leads (Icon (ICLR) 4.7%, Labcorp Holdings (LH) 8.5%).

Which stock has performed better?

Over the past year Labcorp Holdings (LH) returned the most: Icon (ICLR) +19.4%, Labcorp Holdings (LH) +40.0%, NutriBand (NTRB) -4.8%. Over five years, Labcorp Holdings (LH) compounded fastest (Icon (ICLR) -5.7%/yr, Labcorp Holdings (LH) +7.6%/yr, NutriBand (NTRB) +6.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Labcorp Holdings (LH) 0.81%. Icon (ICLR) and NutriBand (NTRB) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Labcorp Holdings (LH) has been the steadiest (Icon (ICLR) 75.1%, Labcorp Holdings (LH) 24.4%, NutriBand (NTRB) 79.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ICLR, LH and NTRB?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Labcorp Holdings (LH) leads on 8. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.